DJIA 17,776.12 -200.19 -1.11%
NASDAQ 4,900.89 -46.56 -0.94%
S&P 500 2,067.89 -18.35 -0.88%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)

13.28 -0.59 (-4.25%)

REAL-TIME: Last trade at

Extended Hours: $13.27 -$0.01 (-0.08%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

SRPT $13.28 -4.25%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.70
Previous Close $13.87
Daily Range $13.15 - $13.92
52-Week Range $11.33 - $40.00
Market Cap $548.6M
P/E Ratio -4.94
Dividend (Yield) $0.00 (0.0%)
Volume 621,828
Average Daily Volume 842,011
Current FY EPS -$4.10




Drug Makers

Sarepta Therapeutics (SRPT) Description

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology. Website:

News & Commentary Rss Feed

3 Easy Ways to Fail When Investing in Biotech Stocks

Our experts help you avoid these common mistakes.

Sarepta Therapeutics (SRPT) Weak On High Volume Today

Sarepta Therapeutics Needs An Ok For NDA Submission

This Upcoming Event Could Affect Sarepta Therapeutics Investors

Emergent BioSolutions Inks Deals for Its Ebola Vaccine - Analyst Blog

Sarepta Therapeutics Inc (SRPT) CEO Christopher Garabedian on Barclays Healthcare Conference - Trans

Sarepta Therapeutics Inc (SRPT) CEO Christopher Garabedian on Barclays Healthcare Conference - Transcript

Insider Trading Alert - SRPT, SNA And TUP Traded By Insiders

Sarepta Therapeutics Inc.'s Price Target Was Slashed By 27% -- Time to Panic?

It's been a rough 12 months for Sarepta Therapeutics, and it got even rougher on Monday following a substantial price target cut from a Wall Street firm. Find out whether this price cut is justified and what investors should consider doing next.

Did Researchers Just Discover a Functional Cure for Duchenne Muscular Dystrophy?

Duchenne muscular dystrophy has no cure, and it often kills its victims by their mid-20s. However, a new international study lends hope that a functional cure to this disease could be in the offing.

Sarepta Therapeutics (SRPT) Q4 2014 Results - Earnings Call Webcast

See More SRPT News...

SRPT's Top Competitors

SRPT $13.28 (-4.25%)
Current stock: SRPT
AMGN $159.85 (-2.71%)
Current stock: AMGN
GILD $98.13 (-2.54%)
Current stock: GILD
CELG $115.35 (-3.89%)
Current stock: CELG